Cargando…

Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)

Objectives To determine the long term clinical effectiveness of laparoscopic fundoplication as an alternative to drug treatment for chronic gastro-oesophageal reflux disease (GORD). Design Five year follow-up of multicentre, pragmatic randomised trial (with parallel non-randomised preference groups)...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, A M, Cotton, S C, Boachie, C, Ramsay, C R, Krukowski, Z H, Heading, R C, Campbell, M K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629902/
https://www.ncbi.nlm.nih.gov/pubmed/23599318
http://dx.doi.org/10.1136/bmj.f1908
_version_ 1782266636758155264
author Grant, A M
Cotton, S C
Boachie, C
Ramsay, C R
Krukowski, Z H
Heading, R C
Campbell, M K
author_facet Grant, A M
Cotton, S C
Boachie, C
Ramsay, C R
Krukowski, Z H
Heading, R C
Campbell, M K
author_sort Grant, A M
collection PubMed
description Objectives To determine the long term clinical effectiveness of laparoscopic fundoplication as an alternative to drug treatment for chronic gastro-oesophageal reflux disease (GORD). Design Five year follow-up of multicentre, pragmatic randomised trial (with parallel non-randomised preference groups). Setting Initial recruitment in 21 UK hospitals. Participants Responders to annual questionnaires among 810 original participants. At entry, all had had GORD for >12 months. Intervention The surgeon chose the type of fundoplication. Medical therapy was reviewed and optimised by a specialist. Subsequent management was at the discretion of the clinician responsible for care, usually in primary care. Main outcome measures Primary outcome measure was self reported quality of life score on disease-specific REFLUX questionnaire. Other measures were health status (with SF-36 and EuroQol EQ-5D questionnaires), use of antireflux medication, and complications. Results By five years, 63% (112/178) of patients randomised to surgery and 13% (24/179) of those randomised to medical management had received a fundoplication (plus 85% (222/261) and 3% (6/192) of those who expressed a preference for surgery and for medical management). Among responders at 5 years, 44% (56/127) of those randomised to surgery were taking antireflux medication versus 82% (98/119) of those randomised to medical management. Differences in the REFLUX score significantly favoured the randomised surgery group (mean difference 8.5 (95% CI 3.9 to 13.1), P<0.001, at five years). SF-36 and EQ-5D scores also favoured surgery, but were not statistically significant at five years. After fundoplication, 3% (12/364) had surgical treatment for a complication and 4% (16) had subsequent reflux-related operations—most often revision of the wrap. Long term rates of dysphagia, flatulence, and inability to vomit were similar in the two randomised groups. Conclusions After five years, laparoscopic fundoplication continued to provide better relief of GORD symptoms than medical management. Adverse effects of surgery were uncommon and generally observed soon after surgery. A small proportion had re-operations. There was no evidence of long term adverse symptoms caused by surgery. Trial registration Current Controlled Trials ISRCTN15517081.
format Online
Article
Text
id pubmed-3629902
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-36299022013-04-24 Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX) Grant, A M Cotton, S C Boachie, C Ramsay, C R Krukowski, Z H Heading, R C Campbell, M K BMJ Research Objectives To determine the long term clinical effectiveness of laparoscopic fundoplication as an alternative to drug treatment for chronic gastro-oesophageal reflux disease (GORD). Design Five year follow-up of multicentre, pragmatic randomised trial (with parallel non-randomised preference groups). Setting Initial recruitment in 21 UK hospitals. Participants Responders to annual questionnaires among 810 original participants. At entry, all had had GORD for >12 months. Intervention The surgeon chose the type of fundoplication. Medical therapy was reviewed and optimised by a specialist. Subsequent management was at the discretion of the clinician responsible for care, usually in primary care. Main outcome measures Primary outcome measure was self reported quality of life score on disease-specific REFLUX questionnaire. Other measures were health status (with SF-36 and EuroQol EQ-5D questionnaires), use of antireflux medication, and complications. Results By five years, 63% (112/178) of patients randomised to surgery and 13% (24/179) of those randomised to medical management had received a fundoplication (plus 85% (222/261) and 3% (6/192) of those who expressed a preference for surgery and for medical management). Among responders at 5 years, 44% (56/127) of those randomised to surgery were taking antireflux medication versus 82% (98/119) of those randomised to medical management. Differences in the REFLUX score significantly favoured the randomised surgery group (mean difference 8.5 (95% CI 3.9 to 13.1), P<0.001, at five years). SF-36 and EQ-5D scores also favoured surgery, but were not statistically significant at five years. After fundoplication, 3% (12/364) had surgical treatment for a complication and 4% (16) had subsequent reflux-related operations—most often revision of the wrap. Long term rates of dysphagia, flatulence, and inability to vomit were similar in the two randomised groups. Conclusions After five years, laparoscopic fundoplication continued to provide better relief of GORD symptoms than medical management. Adverse effects of surgery were uncommon and generally observed soon after surgery. A small proportion had re-operations. There was no evidence of long term adverse symptoms caused by surgery. Trial registration Current Controlled Trials ISRCTN15517081. BMJ Publishing Group Ltd. 2013-04-18 /pmc/articles/PMC3629902/ /pubmed/23599318 http://dx.doi.org/10.1136/bmj.f1908 Text en © Grant et al 2013 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
spellingShingle Research
Grant, A M
Cotton, S C
Boachie, C
Ramsay, C R
Krukowski, Z H
Heading, R C
Campbell, M K
Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)
title Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)
title_full Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)
title_fullStr Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)
title_full_unstemmed Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)
title_short Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)
title_sort minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (reflux)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629902/
https://www.ncbi.nlm.nih.gov/pubmed/23599318
http://dx.doi.org/10.1136/bmj.f1908
work_keys_str_mv AT grantam minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux
AT cottonsc minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux
AT boachiec minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux
AT ramsaycr minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux
AT krukowskizh minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux
AT headingrc minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux
AT campbellmk minimalaccesssurgerycomparedwithmedicalmanagementforgastrooesophagealrefluxdiseasefiveyearfollowupofarandomisedcontrolledtrialreflux